Movex® – recovery of joints and spine on “turnkey” basis

Composition of active ingredients: 

1 tablet contains - kalium diclofenac 50 mg, glucosamine sulfate 500 mg,
chondroitin sulfate natrium 400 mg

Dosage form: 

coated tablets in bottles №30 and №60,
in carton package

  • Fast pain relief with clinically proven efficacy*
  • Stimulates the restoration of cartilage tissue, joints and spine
  • “Lubricates” joints surface and stimulates production of synovial fluid
Children from 18 years

Administration and Dosages

For adults: take 1 tablet 3 times a day after meal.
The treatment schedule is adjusted individually.
Do not take more than 3 weeks.
On doctor’s prescription the treatment could be longer.
After pain syndrome elimination and doctor's advice Movex Comfort may be applied.

Pharmacotherapeutic group

Ingredients are  applying  for the musculoskeletal system treatment.

Nonsteroid anti-inflammatory and antirheumatic drugs. АТС М01АХ

Pharmacological properties

The medicine  has anti-inflammatory, analgesic, regenerative and chondroprotective effect. Slows down the process of cartilage damage and bone resorption, restores cartilage, accelerates the formation of bone callus trauma, helps restore joint function.

Glucosamine is the substrate of cartilage construction and stimulates the regeneration of cartilage tissue. Glycosaminoglycans and proteoglycans are the part of a complicated matrix the cartilage composed of. Glucosamine is included as a compound of endogenous glycosaminoglycans of cartilage, stimulates the production of proteoglycans and increases the absorption of sulphate by articular cartilage. Therefore, glucosamine compensates the endogenous deficiency of glucosamine. It participates in the biosynthesis of proteoglycans and hyaluronic acid, consequently resist the progression of degenerative processes in the joints, the spine and surrounding soft tissues; It stimulates the production of chondroitin acids, normalizes calcium deposition in bone tissue, contributes to restoration of the articular function and disappearance of pain syndrome.

Chondroitin sulfate has a chondroprotective effect, stimulates the regeneration of cartilage tissue, exhibits the anti-inflammatory and analgesic effect. Chondroitin sulfate natrium, which affects the calcium-phosphorus metabolism in cartilage, is represented as a macromolecular mucopolysaccharide (m.m. 20000-30000). The drug slows the bone tissue resorption and reduces the calcium loss, slows the cartilage degeneration. . Prevents the compression of the connective tissue, “lubricates” the joint surfaces and normalizes the joint fluid production.
Diclofenac kalium - is NSAID with analgesic, anti-inflammatory and antipyretic activity, has a rapid onset of action, which is particularly important for the treatment of acute pain in conditions of inflammation. The mechanism of action involves a non-selective blockade of the synthesis of the enzyme cyclooxygenase, which leads to the inhibition of synthesis of prostaglandins, which play a major role in the development of inflammation, pain and fever.
Diclofenac kalium suppresses phase advantageously exudation, proliferation to a lesser extent by reducing collagen synthesis and consequent hardening of tissues.
Reduces pain at rest and in motion, reduces the appearance of morning stiffness of the joints, swelling of soft tissue, improves the functional state of the musculoskeletal system.

To obtain full information please see the Patient Leaflet Information.


The treatment of diseases of the musculoskeletal system with symptoms of inflammation, pain, degenerative-dystrophic changes in the cartilaginous parts of the joints and spine, decreased mobility of the joints.

Degenerative-dystrophic diseases of joints and spine:

  • osteoarthritis,
  • periarthritis (including knee, hip joints, intervertebral osteochondrosis, spondylarthrosis)
  • rheumatoid arthritis,
  • fractures and traumas (for accelerating the formation of callus)


Individual hypersensitiveness to any of the medicine ingredients, phenylketonuria,  predisposition to exsanguination, thrombosis, ulcer of stomach or stercolar ulcer, liver and renal dysfunction at decompensation stage. Do not use in case of shellfish allergy.  

To obtain full information please see the Patient Leaflet Information.

Do not exceed the recommended dose.

Do not take the medicine if you are pregnant or breast feeding.

To obtain full information please see the Patient Leaflet Information.

Store in the original package below +25°С.
Keep out of the reach of children.

R.S.  MOH  of  Ukraine № UA/10205/01/01 of 19.08.2014